Serzone Articles
Warning on ED drug-drug interactions
19 January 2009
ACP guidelines recommend 2nd-generation antidepressants
24 November 2008
US FDA posts DSOB meeting summary
15 August 2005
B-MS to pull Serzone from US market
31 May 2004
B-MS reports 1st-qtr earnings jump 22%
3 May 2004
Green light for 150mg Wellbutrin generics
29 March 2004
Public Citizen to sue FDA over Serzone
22 March 2004
Indian firms win US approvals, other news
6 October 2003
B-MS reviewing Serzone in Canada
8 September 2003
Stock Commentary week to Jan 13 - New York
20 January 2003
B-MS to withdraw nefazodone in Europe
13 January 2003
B-MS to add warning to Serzone labeling
10 December 2001
Bristol-Myers Squibb's "solid year" sees net earnings rise 13%
25 January 2001
B-MS net earnings increase 13%
23 October 2000
B-MS up on strong sales of Glucophage
24 July 2000
Warnings To Be Added To US Propulsid Labeling
1 July 1998
US Quarterly Financial Results Round-Up
23 April 1998
Expanded Warnings For J&J's Hismanal
11 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Solid Growth For US Firms Despite Strong $
24 July 1997
New Data With B-MS' Serzone
3 July 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Cephalon To Promote B-MS Antidepressant
4 March 1996
Medi-Cal Formulary Additions
4 March 1996
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
Bristol-Myers research operations
31 July 1995
Solid 2nd Qtr Earnings Growth For US Drugmakers
17 July 1995
Trials To Assess Serzone Side Effect Advantage
12 June 1995
B-MS' Nefazodone Launched In UK
17 April 1995
Bristol-Myers Squibb Has "Best Combo Of Businesses"
20 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Serzone Priced At Discount To SSRIs In USA
16 January 1995
B-MS' Nefazodone: Launch Soon In USA
9 January 1995
B-MS' Nefazodone Launched In 1st Market
3 October 1994
NEW PLAYER IN US DEPRESSION MARKET
25 April 1994
NEW APPROVALS CHANGE DEPRESSION MARKET
17 January 1994
US PANEL BACKS B-MS' SERZONE
9 August 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
CLINICAL EFFICACY OF B-MS' NEFAZODONE
12 April 1993
STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB
20 April 1992
Showing 1-48 of 48 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
